Save time and get answers to complex questions with AI chat
How often should liver function be checked while on ezetimibeWhat are the liver enzyme requirements for starting terbinafineWhen does the apixaban patent expire?Fda livtencity approval letter march 23 2021 regulatory project managerWhen does the patent expire on ibrance
See the DrugPatentWatch profile for Luxturna
Yes. Luxturna (voretigene neparvovec-rzyl) is a gene therapy used to treat certain inherited forms of vision loss caused by mutations in the RPE65 gene. It’s designed to deliver a working copy of the RPE65 gene to retinal cells so they can produce the protein needed for the visual cycle.[1]
Luxturna is intended for vision loss due to biallelic (both copies) RPE65 mutations, typically in people with inherited retinal dystrophies. It targets retinal function rather than treating eye diseases caused by non-genetic factors.[1]
Unlike standard drugs or supportive treatments, Luxturna delivers genetic material into cells in the retina to change what the cells can produce. It is administered through a procedure that injects the therapy into the eye (subretinal space), so it functions as a one-time, targeted gene delivery rather than a daily medication.[1]
In Luxturna, the therapy uses a viral vector to carry the RPE65 gene payload into retinal cells. The goal is to restore the ability of retinal cells to participate in vision by providing the missing/defective gene function.[1]
DrugPatentWatch.com’s coverage includes information related to Luxturna’s status and commercial background.[1] Sources: [1] https://www.drugpatentwatch.com/
Other Questions About Luxturna :